Deczuba 50mg Injection

Introduction to Deczuba 50 mg Injection

Deczuba 50mg Injection is used in the treatment of blood cancer called Acute Myeloid Leukaemia (AML). It is also used to treat patients with myelodysplastic syndrome (MDS). It may be used to treat other conditions, as determined by the doctor.

The injection is typically administered intravenously by a healthcare professional, usually in a hospital or specialized clinic. The dosing schedule and duration of treatment depend on the type of cancer being treated and the patient’s overall health and response to the medication.

Deczuba is often used for cancers such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), conditions where abnormal blood cell production occurs. Before taking it, tell your doctor if have heart disease, liver, or kidney problems or are taking any medicines to treat infections.

Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. Use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Uses of Deczuba 50 mg

Deczuba 50 mg Decitabine Injection is primarily used in the treatment of certain types of cancer. Its key uses include:

• Myelodysplastic Syndromes (MDS)
• Acute Myeloid Leukemia (AML)
• Hypomethylating Agent
• Maintenance of Remission

How Does Deczuba 50 Works?

Deczuba 50 mg Injection has an active ingredient; Decitabine. Decitabine is a hypomethylating agent which hypomethylates DNA by inhibiting DNA methyltransferase. Decitabine incorporates into DNA strands upon replication.

After that when DNA methyltransferases (DNMTs), are engaged to bind to the DNA & to replicate the methylation to the daughter strand, DNMTs are bound to Decitabine irretrievably & cannot disengage.

Therefore, the action of Decitabine is division-dependant, which means the cells have to divide in order for the pharmaceutical to act. Therefore, cancer cells which divide much faster than most other cells in the body will be severely affected by Decitabine because they replicate more.

Side Effects of Deczuba 50

Common Side Effects

• Nausea and Vomiting
• Fatigue
• Low Blood Cell Counts
• Fever
• Appetite Loss
• Diarrhea

Serious Side Effects

• Severe Bone Marrow Suppression
• Severe Bleeding
• Liver Problems
• Kidney Issues

Dosage of Deczuba 50 mg

The typical dosage of Deczuba 50 mg Decitabine Injection for adults with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) is 15 mg/m², administered as an intravenous infusion once every 8 hours for 3 days in a 6-week cycle. For AML, the treatment cycle may vary based on the patient’s condition and response to therapy.

Dosage adjustments may be needed based on the patient’s tolerance and blood counts. The exact dosage and schedule should be determined by an oncologist, depending on the individual’s specific medical needs and health status.

Warnings & Precautions

Here are the Warnings & Precautions for Deczuba 50 mg Decitabine Injection:

1. Infection Risk:

• Due to low white blood cell counts, there is an increased risk of infection. Patients should avoid exposure to infections and report symptoms promptly.

2. Pregnancy and Breastfeeding:

• Pregnant women should avoid Deczuba, as it may harm the fetus. It is also not recommended during breastfeeding.

3. Renal Impairment:

• Dose adjustments may be necessary for patients with kidney problems, as Deczuba can affect renal function.

4. Tumor Lysis Syndrome:

• In some cases, Deczuba may cause tumor lysis syndrome, a condition resulting from the rapid breakdown of cancer cells. Proper hydration and monitoring are essential.

5. Fertility:

• Deczuba may affect fertility in both men and women, so fertility preservation should be discussed before starting treatment.

6. Concomitant Medications:

• Inform your doctor about all other medications you are taking, as drug interactions can alter the effects or increase side effects of Deczuba.

Frequently Asked Questions

1. Is Deczuba 50mg Injection a vesicant?

Ans. Deczuba 50mg Injection is not a vesicant and is not known to cause severe local tissue damage upon extravasation (leaking of injected Deczuba 50mg Injection into the surrounding tissues from the site of administration) when injected.

2. How effective is Deczuba 50mg Injection?

Ans. The effectiveness of Deczuba 50mg Injection depends upon several factors including the patient’s clinical condition, number of treatment cycles etc. and may vary depending upon the individual response.

3. Does Deczuba 50mg Injection cause hair loss?

Ans. Yes. Hair loss (alopecia) is among the known side effects of Deczuba 50mg Injection.

4. How is Deczuba 50mg Injection administered?

Ans. Deczuba 50mg Injection comes as a powder to be to be added to fluid and injected slowly over 3 hours into a vein (slow i.v infusion) by a doctor who is experienced in giving chemotherapy medications for cancer in a hospital or a clinic.